US Pen Needles

The US pen needles market is projected to reach USD 1.53 billion by 2031 from USD 0.93 billion in 2026 at a CAGR of 10.4% during the forecast period.

The increased incidence of diabetes, growing embracement of insulin pens, and stronger patient preference for convenience and safety are driving the per-patient per-use of needles, which and turn drive the U.S. pen needles market forward. The utilization of shorter, thinner, and safety-engineered needles tends to create a higher demand. But market growth is restrained by pricing pressure, product commoditization, and reimbursement variability. Severely affecting the supply of needles, more stringent sharps disposal regulations and portfolio realignments by dominant players are underway. The seed opportunities are, however, numerous: differentiation can be achieved across a wide range, from ultra-thin to safety-shield technologies, and the compatibility with most insulins can be enhanced. Moreover, some innovative needle concepts can be developed in this space. Entering through retail pharmacy channel partnerships, OEM supply partnerships, and home-care diabetes management programs may also be part of the action to increase the uptake of premium products.

This report segments the pen needles market by type, length, application, mode of purchase, setting, and region.

To know about the assumptions considered for the study download the pdf brochure

Prominent players in this market include Embecta Corp. (US), Novo Nordisk A/S (Denmark), MTD Medical Technology and Devices (Italy), B. Braun SE (Germany), Owen Mumford (UK), Terumo Corporation (Japan), NIPRO Corporation (Japan), Allison Medical, Inc. (US), AdvaCare Pharma (US), Berpu Medical Technology Co., Ltd. (China), ARKRAY, Inc. (Japan), GlucoRx Limited (UK), HTL-STREFA (Poland), UltiMed, Inc. (US), Artsana Group (Italy), PromiseMed Medical Devices Inc. (Canada), Montmed, Inc. (Canada), Trividia Health, Inc. (US), VOGT Medical Vertrieb GmbH (Germany), Van Heek Medical (Netherlands), Simple Diagnostics (US), IYON Medical (Turkey), Links Medical Products, Inc. (US), and MHC Medical Products, LLC (US).

Embecta Corp. (US)

A major player in the US pen needle market, Embecta has extensive experience delivering insulin, dating back to its predecessor, BD, many decades ago. Its clinical product portfolio is comprehensive and includes the reputable Nano and Ultra Fine pen needle lines of products, all with safety options, and is accepted by providers and pharmacies. With its global footprint and high annual volume, Embecta can offer competitive pricing. This is complemented by the reliable supply of products, due in part to distributor relationships with hospitals, wholesalers, and retail pharmacies. Quality products, safety-engineered choices, and continuous safety options have enabled continual innovations to attract more users of choice for clinicians and payors, allowing for the retention of market share, even amid shifting therapeutic trends and pricing pressures.

Novo nordisk a/s (denmark)

Novo Nordisk is a key player in the US pen-needle market, as it combines a long legacy in insulin delivery (launching the world’s first pen needle) with an integrated pens-and-needles ecosystem (NovoFine, NovoTwist) that clinicians and patients trust for its compatibility and comfort. Its extensive, global manufacturing footprint and strategic capacity investments support reliable supply and scale economies that protect margins and pricing competitiveness. The company’s strong brand, deep distribution through pharmacies and hospitals, and continuous product refinement (fine-gauge, low-trauma, and safety variants) secure formulary placements and payer contracts, making Novo Nordisk a market anchor despite pricing and therapeutic shifts.

B. braun se (germany)

B. Braun is a significant player in the US pen needles market, thanks to its long-standing expertise in needle technology and its uncompromising safety-engineered solutions, supported by strong relationships with hospitals, clinics, and outpatient diabetes care settings. The company manufactures high-quality, low-trauma needle products, leveraging its global manufacturing capabilities, which include precision engineering, to emphasize patient comfort and consistency in injection. B. Braun's strength in the area of safety devices and the prevention of sharps injuries positions it well as regulations become increasingly focused on safe injection practices. The robust distribution channel, dependable supply, and trusted brand reputation favor achieving mass adoption. At the same time, continuous innovation in fine-gauge and ergonomic designs keeps B. Braun relevant in the face of pricing pressures and market commoditization.

Market Ranking

The US pen needles market is consolidated, with prominent players accounting for 76.0% of the total market share in 2025. Some of the players dominating the market include Embecta Corp., Novo Nordisk, B.Braun, Terumo Corporation, and Nipro Corporation, among others. Key players from both abroad and at home dominate the US pen needles market, benefiting from strong distribution and reimbursement advantages. The growth of the pen needle market is primarily attributed to the increasing adoption of home care services, the rise of digital pharmacies, and the growing prevalence of diabetes. Meanwhile, smaller players from different regions are gaining a foothold by providing their products at competitive prices. These products serve to increase price competition further and enhance patient access.

Related Reports:

US Pen Needles Market by Type (Standard Pen Needles, Safety Pen Needles), Length (8mm, 5mm), Setting (Home Care Settings), Application (Glucagon-like Peptide-1 Therapy), Mode of Purchase (Over-the-counter Purchase, Online Purchase)-Forecast to 2031

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com